

September 10, 2013

Hello,

If you are looking for an opportunity to demonstrate national leadership and are seeking ways to impact the care that is delivered to Canadians with cancer, you may be interested in participating in the pan-Canadian Oncology Drug Review (pCODR).

pCODR was established by the provincial and territorial Ministries of Health to assess the clinical evidence and cost effectiveness of new cancer drugs and to use this information to make recommendations to the provinces and territories to guide their drug funding decisions.

pCODR began accepting submissions in July 2011. To date, 19 submissions have been completed. In anticipation of an increase in submissions for hematologic malignancies, pCODR is currently recruiting a **hematologist** to sit as a member of the pCODR Expert Review Committee (pERC).

In addition, pCODR continuously recruits oncologists to sit on the 11 clinical guidance panels, which are structured around specific tumour types, e.g. breast, endocrine, gastrointestinal, genitourinary, head and neck, leukemia, lymphoma and myeloma, lung, melanoma, neuro-oncology, sarcoma. We are also in need of economists, with knowledge of pharmacoeconomics, to participate on the economic guidance panels.

The [nomination package](#) provides a clear outline of the criteria and process to become a pERC member or a member of pCODR's clinical or economic guidance panels.

Nominations/submissions for the hematologist pERC member position will be accepted until **5 p.m. EDT, October 18, 2013**. All other applications for clinical or economic panels will be accepted on an on-going basis.

If you have any questions, please contact nominations@pcodr.ca.

Sincerely,



Mona Sabharwal
Executive Director